Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome

References

• Deswal R, Narwal V, Dang A, et al. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):1–5. doi:10.4103/jhrs.JHRS_95_18.
   PubMedGoogle Scholar
• Morgante G, Massaro MG, Di Sabatino A, et al. Therapeutic approach for metabolic disorders and infertility in women with PCOS. Gynecol Endocrinol. 2018;34(1):4–9. doi:10.1080/09513590.2017.1370644.
   PubMed Web of Science ®Google Scholar
• Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest. 2006;29(3):270–280. doi:10.1007/BF03345554.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(1):162–168. doi:10.1210/jc.2007-1834.
   PubMed Web of Science ®Google Scholar
• Costello MF, Shrestha B, Eden J, et al. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a cochrane review. Hum Reprod. 2007;22(5):1200–1209. doi:10.1093/humrep/dem005.
   PubMed Web of Science ®Google Scholar
• Gariani K, Hugon-Rodin J, Philippe J, et al. Association between polycystic ovary syndrome and venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2020;185:102–108. doi:10.1016/j.thromres.2019.11.019.
   PubMed Web of Science ®Google Scholar
• Mathur R, Alexander CJ, Yano J, et al. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol. 2008;199(6):596–609. doi:10.1016/j.ajog.2008.09.010.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Orrù B, Grandi G, et al. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35(3):198–206. doi:10.1080/09513590.2018.1540578.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metabol. 1997;82:4075–4079.
   PubMed Web of Science ®Google Scholar
• Awuchi CG, Echeta KC. Current developments in sugar alcohols: chemistry, nutrition, and health concerns of sorbitol, xylitol, glycerol, arabitol, inositol, maltitol, and lactitol. Int J Adv Acad Res. 2019;5:1–33.
   Google Scholar
• Thomas MP, Mills SJ, Potter BV. The “other” inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo-inositol chemistry). Angew Chem Int Ed Engl. 2016;55(5):1614–1650. doi:10.1002/anie.201502227.
   PubMed Web of Science ®Google Scholar
• Dakin K, Li WH. Cell membrane permeable esters of D-myo-inositol 1, 4, 5-trisphosphate. Cell Calcium. 2007;42(3):291–301. doi:10.1016/j.ceca.2006.12.003.
   PubMed Web of Science ®Google Scholar
• López-Gambero AJ, Sanjuan C, Serrano-Castro PJ, et al. The biomedical uses of inositols: a nutraceutical approach to metabolic dysfunction in aging and neurodegenerative diseases. Biomed. 2020;8:295.
   Google Scholar
• Anastassakis K, editors. Inositol (vitamin B8). In: Androgenetic alopecia from a to Z. Springer, Cham; 2022. p. 343–345.
   Google Scholar
• Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61(2):111–117. doi:10.1507/endocrj.ej13-0423.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Dante G, Neri I. The ratio of MI to DCI and its impact in the treatment of polycystic ovary syndrome: experimental and literature evidences. In: genazzani, A., Tarlatzis, B., editors. Frontiers in gynecological endocrinology. ISGE Series. Springer, Cham; 2016. doi:10.1007/978-3-319-23865-4_13.
   Google Scholar
• Unfer V, Carlomagno G, Papaleo E, et al. Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci. 2014;21(7):854–858. doi:10.1177/1933719113518985.
   PubMed Web of Science ®Google Scholar
• Dinicola S, Unfer V, Facchinett F, et al. Inositols: from established knowledge to novel approaches. Int J Mol Sci. 2021;22(19):10575. doi:10.3390/ijms221910575.
   PubMed Web of Science ®Google Scholar
• Downes CP, Macphee CH. Myo-inositol metabolites as cellular signals. Eur J Biochem. 1990;193(1):1–18. doi:10.1111/j.1432-1033.1990.tb19297.x.
   PubMedGoogle Scholar
• Mukai T, Kishi T, Matsuda Y, et al. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol. 2014;29(1):55–63. doi:10.1002/hup.2369.
   PubMed Web of Science ®Google Scholar
• Janiri L, D’Ambrosio F, Di Lorenzo C. Combined treatment of myo-inositol and D-chiro-inositol (80: 1) as a therapeutic approach to restore inositol eumetabolism in patients with bipolar disorder taking lithium and valproic acid. Eur Rev Med Pharmacol Sci. 2021;25(17):5483–5489. doi:10.26355/eurrev_202109_26657.
   PubMed Web of Science ®Google Scholar
• Ziffra M. Panic disorder: a review of treatment options. Ann Clin Psychiatry. 2021;33(2):124–133. doi:10.127788/acp.0014.
   PubMedGoogle Scholar
• Cantelmi T, Lambiase E, Unfer VR, et al. Inositol treatment for psychological symptoms in polycystic ovary syndrome women. Eur Rev Med Pharm Sci. 2021;25:2383–2389.
   PubMed Web of Science ®Google Scholar
• Ramp P, Lehnert A, Matamouros S, et al. Metabolic engineering of Corynebacterium glutamicum for production of scyllo-inositol, a drug candidate against Alzheimer’s disease. Metab Eng. 2021;67:173–185. doi:10.1016/j.ymben.2021.06.011.
   PubMed Web of Science ®Google Scholar
• Carlomagno G, Unfer V, Buffo S, et al. Myo-inositol in the treatment of premenstrual dysphoric disorder. Human Psychopharmacology. 2011;26(7):526–530. doi:10.1002/hup.1241.
   PubMed Web of Science ®Google Scholar
• Gerli S, Papaleo E, Ferrari A, et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;27(18):8323. doi:10.26355/eurrev_202309_33752.
   Google Scholar
• Unfer V, Carlomagno G, Dante G, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509–515. doi:10.3109/09513590.2011.650660.
   PubMed Web of Science ®Google Scholar
• Bevilacqua A, Bizzarri M. Physiological role and clinical utility of inositols in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:129–139. doi:10.1016/j.bpobgyn.2016.03.007.
   PubMed Web of Science ®Google Scholar
• Calcaterra V, Verduci E, Cena H, et al. Polycystic ovary syndrome in insulin-resistant adolescents with obesity: the role of nutrition therapy and food supplements as a strategy to protect fertility. Nutrients. 2021;13(6):1848. doi:10.3390/nu13061848.
   PubMed Web of Science ®Google Scholar
• da Silva Rosa SC, Nayak N, Caymo AM, et al. Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue. Physiol Rep. 2020;8(19):e14607. doi:10.14814/phy2.14607.
   PubMed Web of Science ®Google Scholar
• Davinelli S, Nicolosi D, Di Cesare C, et al. Targeting metabolic consequences of insulin resistance in polycystic ovary syndrome by D-chiro-inositol and emerging nutraceuticals: a focused review. J Clin Med. 2020;9(4):987. doi:10.3390/jcm9040987.
   PubMed Web of Science ®Google Scholar
• El-Roeiy A, Chen X, Roberts VJ, et al. Expression of the insulin-like growth factor (IGF)-I and IGF-II and the IGF-I, IGF-II and insulin receptor genes and localization of the gene products in the human ovary. J Clin Endocrinol Metab. 1993;77(5):1411–1418. doi:10.1210/jc.77.5.1411.
   PubMed Web of Science ®Google Scholar
• El-Roeiy A, Roberts VJ, Shimasaki S, et al. Expression of the gene encoding the insulin-like growth factors (IGF-I and IGF-II), the IGF-I and insulin receptors and IGF binding proteins (IGFBPs 1–6), and the localization of their gene products in normal and polycystic ovary syndrome ovaries. J. Clin. Endocrinol. Metab. 1994;78:1488–1496.
   PubMed Web of Science ®Google Scholar
• Bergh C, Carlsson B, Olsson JH, et al. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril. 1993;59(2):323–331. doi:10.1016/s0015-0282(16)55675-1.
   PubMed Web of Science ®Google Scholar
• Nahum R, Thong KJ, Hillier SG. Metabolic regulation of androgen production by human thecal cells in vitro. Hum Reprod. 1995;10(1):75–81. doi:10.1093/humrep/10.1.75.
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327(7421):951–953. doi:10.1136/bmj.327.7421.951.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Christakou CD, Kandaraki E, et al. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010;162(2)2010:193–212. doi:10.1530/EJE-09-0733.
   PubMed Web of Science ®Google Scholar
• Fedeli V, Catizone A, Querqui A, et al. The role of inositols in the hyperandrogenic phenotypes of PCOS: a re-reading of larner’s results. Int J Mol Sci. 2023;24(7):6296. doi:10.3390/ijms24076296.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marinaro F, Tondelli D, et al. Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol. Reprod Biol Endocrinol. 2016;14(1):52. doi:10.1186/s12958-016-0189-2.
   PubMedGoogle Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340(17):1314–1320. doi:10.1056/NEJM199904293401703.
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon J-P, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8(6):417–423. doi:10.4158/EP.8.6.417.
   PubMedGoogle Scholar
• Roseff S, Montenegro M. Inositol treatment for PCOS should be science-based and not arbitrary. Int J Endocrinol. 2020;2020:6461254–6461258. doi:10.1155/2020/6461254.
   PubMed Web of Science ®Google Scholar
• Chiu TTY, Rogers MS, Law ELK, et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002;17(6):1591–1596. doi:10.1093/humrep/17.6.1591.
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Baillargeon J-P, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007;23(12):700–703. doi:10.1080/09513590701672405.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Vitagliano A, Noventa M, et al. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and metanalysis of randomized controlled trials. Arch Gynecol Obstet. 2018;298(4):675–684. doi:10.1007/s00404-018-4861-y.
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Rizzo P, et al. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011;15(4):452–457.
   PubMed Web of Science ®Google Scholar
• Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011;95(8):2515–2516. doi:10.1016/j.fertnstert.2011.05.027.
   PubMed Web of Science ®Google Scholar
• Kamenov Z, Gateva A. Inositols in PCOS. Molecules. 2020;25(23):5566. doi:10.3390/molecules25235566.
   PubMed Web of Science ®Google Scholar
• Unfer V, Facchinetti F, Orrù B, et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–658. doi:10.1530/EC-17-0243.
   PubMed Web of Science ®Google Scholar
• Zeng L, Yang K. Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. Endocrin. 2018;59(1):30–38. doi:10.1007/s12020-017-1442-y.
   Google Scholar
• Nordio M, Basciani S, Camajani E. The 40: 1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23(12):5512–5521. doi:10.26355/eurrev_201906_18223.
   PubMed Web of Science ®Google Scholar
• Bevilacqua A, Dragotto J, Giuliani A, et al. Myo-inositol and D-chiro-inositol (40: 1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J Cell Physiol. 2019;234(6):9387–9398. doi:10.1002/jcp.27623.
   PubMed Web of Science ®Google Scholar
• Arya BK, Haq AU, Chaudhury K. Oocyte quality reflected by follicular fluid analysis in polycystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism. Med Hypotheses. 2012;78(4):475–478. doi:10.1016/j.mehy.2012.01.009.
   PubMed Web of Science ®Google Scholar
• Mendoza N, Diaz-Ropero MP, Aragon M, et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019;35(8):695–700. doi:10.1080/09513590.2019.1576620.
   PubMed Web of Science ®Google Scholar
• Mendoza N, Galan MI, Molina C, et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2020;36(5):398–401. doi:10.1080/09513590.2019.1681959.
   PubMed Web of Science ®Google Scholar
• Garzon S, Laganà AS, Monastra G. Risk of reduced intestinal absorption of myo-inositol. Expert Opin Drug Metab Toxicol. 2019;15(9):697–703. doi:10.1080/17425255.2019.1651839.
   PubMed Web of Science ®Google Scholar